Tuesday, June 27, 2017

Who will pay for CRISPR?

The ruckus over the CRISPR gene-editing system hides a dark reality: its high cost may make it unaffordable and questions remain whether most insurance companies will pay for it. As CRISPR begins to move forward in clinical trials, there are some signals about how it may - or may not - be received commercially. Other types…

No comments :

Post a Comment